The health authorities in Britain have given the green light to use a drug that treats the most aggressive types of breast cancer that affect women.

And the British newspaper "Daily Mail" reported that the new drug "pembrolizumab" is intended to fight triple negative breast cancer, and is responsible for one in every four deaths caused by breast cancer in general.

Researchers say that immunotherapy, which is given intravenously in addition to chemotherapy and before resorting to surgical treatment, can lead to the disappearance of any detectable tumors.

The drug reduces the chances of the disease progressing in the body by 40 percent.

And the National Institute for Health and Care Excellence, one of the bodies affiliated with the Public Health Authority in Britain, granted approval to give the drug to patients with triple negative breast cancer, due to the risk of this cancer returning after the end of treatment.

"The prognosis for triple-negative breast cancer is relatively poor, and there are few effective treatments compared to other types of the disease," says expert Helen Knight.